AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 161 min read$TEVA

Kalif Eliyahu Sharon sold $3.6M of TEVA

Kalif Eliyahu Sharon (EVP, Chief Financial Officer) sold 106,563 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.10 ($3.63M total) on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kalif Eliyahu Sharon
Published Jun 16, 2026, 12:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEVA
Neutral
medium confidence
Mentioned
$TEVA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

The disclosure provides incremental information about insider behavior but does not introduce new operating or financial fundamentals for TEVA.

02

Market read

A CFO open-market sale worth ~$3.63M is disclosed; 10b5-1 status suggests limited fundamental implications.

03

What to watch

Traders may over-weight insider sales; without accompanying guidance, litigation, or operational updates, the signal is mostly sentiment and positioning rather than a catalyst.

Relevance 5/10Novelty 6/10Timing: SEC Form 4 filed 2026-06-16 for a 2026-06-11 sale

Background

The article is an SEC Form 4 insider transaction disclosure for TEVA, showing an officer sale executed under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$TEVANeutralMedium confidence
Context

TEVA CFO Kalif Eliyahu Sharon sold 106,563 shares in an open-market transaction worth about $3.63M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure, but the transaction is explicitly pre-arranged (10b5-1), which typically dampens market reaction versus discretionary selling.

Market effects

Sector

No direct sector read-across; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a bearish view on TEVA fundamentals.

Key entities

  • issuer
    TEVA

    TEVA Pharmaceutical Industries Ltd; subject of the insider transaction disclosure.

  • insider
    Kalif Eliyahu Sharon

    TEVA EVP and Chief Financial Officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

OCT 13
$TEVAHigh

Teva wins FDA approval for schizophrenia injection

Teva Pharmaceuticals received FDA approval for a new injection form of olanzapine, an antipsychotic drug for schizophrenia. The company claims this could improve patient adherence compared to daily oral treatment, potentially reducing relapse risks. Olanzapine is the most widely prescribed atypical antipsychotic.

lifesciencesweden.se1 min
OCT 13
$TEVAHigh

USFDA Approves Teva's Once-Monthly Schizophrenia Injection Weltruza

Teva, in partnership with Medincell, received USFDA approval for Weltruza, a once-monthly schizophrenia injection. Teva expects to launch the drug in the US soon. Medincell's technology enables extended-release medication. Analysts note potential for improved treatment adherence. Medincell may receive up to $112 million in milestone payments and royalties. Teva's shares rose 2% in Tel Aviv; Medincell's shares gained 16.9% in Paris.

medicaldialogues.in2 min
OCT 12
$TEVAHigh

FDA Approves Once-Monthly Olanzapine Injection for Adults with Schizophrenia

The FDA approved Teva Pharmaceuticals' once-monthly olanzapine injection (Weltruza) for adults with schizophrenia. The subcutaneous injection uses novel technology for steady release, eliminating post-injection monitoring. The approval was based on the Phase 3 SOLARIS trial, showing significant symptom reduction and a safety profile consistent with oral olanzapine.

drugtopics.com3 min
OCT 12
$TEVAHigh

FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine injection, received FDA approval for treating schizophrenia. The treatment requires no loading doses or postinjection monitoring. It will be available in doses of 318 mg, 425 mg, and 531 mg, corresponding to daily oral olanzapine doses. The approval was based on the SOLARIS trial, which showed significant improvements in symptoms compared to placebo.

pharmacytimes.com3 min
OCT 12
$TEVAMed

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva Pharmaceutical Industries received FDA approval for Weltruza, a once-monthly injection for schizophrenia. Shares rose 4.7% on Oct. 9. The drug will launch in the U.S. soon, offering an alternative to daily oral treatments. Teva's Uzedy, another schizophrenia treatment, saw sales surge 51% YoY to $140M in H1 2026. Teva also progresses with its branded pipeline, including duvakitug for inflammatory bowel diseases.

zacks.com6 min